RPC 4046

Drug Profile

RPC 4046

Alternative Names: ABT-308; RPC-4046

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Receptos
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic oesophagitis
  • Discontinued Allergic asthma

Most Recent Events

  • 09 Jan 2017 Celgene plans a phase III trial for Eosinophilic oesophagitis
  • 15 Oct 2016 Pharmacodynamics and adverse event data from a phase II trial in Eosinophilic-oesophagitis presented at the 24th United European Gastroenterology Week (UEGW-2016)
  • 11 Feb 2015 RPC 4046 receives Orphan Drug status for Eosinophilic oesophagitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top